Table 6. Factors predictive of SVR in HIV-infected patients with chronic HCV-1/6 or HCV-2/3 infection.
| Variables* | HCV-1/6 infection (N = 53) |
HCV-2/3 infection (N = 39) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis |
Multivariate analysis† |
Univariate analysis |
Multivariate analysis† |
|||||||
| SVR (n = 36) | Non-SVR (n = 17) | p value | OR (95% CI) | p value | SVR (n = 30) | Non-SVR (n = 9) | p value | OR (95% CI) | p value | |
| Mean age (SD), y | 37(8) | 45 (10) | 0.005 | 0.88 (0.78–0.99) | 0.04 | 35 (7) | 35 (9) | 0.95 | — | — |
| Sex (male vs. female) | 34/2 (94/6) | 14/3 (82/18) | 0.31 | — | — | 27/3 (90/10) | 9/0 (100/0) | 0.99 | — | — |
| Mean ALT quotient (SD) | 3.0 (3.5) | 1.9 (1.1) | 0.18 | — | — | 3.3 (2.7) | 3.2 (3.3) | 0.47 | — | — |
| HIV risk behavior (MSM vs. non-MSM) | 23/13 (64/36) | 7/10 (41/59) | 0.15 | — | — | 25/5 (83/17) | 7/2 (78/22) | 0.65 | — | — |
| On HAART | 34 (94) | 15 (88) | 0.59 | — | — | 26 (87) | 8 (89) | 0.99 | — | — |
| HIV-RNA <50 copies/mL | 27 (75) | 7 (41) | 0.30 | — | — | 20 (67) | 4 (44) | 0.27 | — | — |
| Mean CD4 cell count (SD), 106 cells/L | 427 (70) | 389 (71) | 0.08 | 1.01 (0.99–1.02) | 0.38 | 462 (101) | 388(65) | 0.05 | 1.01 (0.99–1.03) | 0.06 |
| HCV RNA (SD), log10 IU/mL | 6.06 (1.25) | 6.99 (0.58) | 0.006 | 0.18 (0.03–0.98) | 0.03 | 5.78 (1.72) | 6.33 (0.86) | 0.35 | — | — |
| IL28B rs8099917 genotype (TT vs. non-TT) | 28/8 (78/22) | 8/9 (47/53) | 0.03 | 5.52 (1.55–12.2) | 0.02 | 26/4 (87/13) | 5/4 (56/46) | 0.07 | 2.78 (0.86–4.23) | 0.07 |
| METAVIR fibrosis stage (<F2 v.s. ≥F2)¶ | 20/16 (56/44) | 6/11 (35/65) | 0.24 | — | — | 17/12 (59/41) | 5/4 (56/44) | 0.73 | — | — |
| RVR (yes vs. no) | 20/16 (56/44) | 2/15 (12/88) | 0.003 | 9.62 (3.89–15.3) | 0.007 | 23/7 (77/23) | 5/4 (56/44) | 0.24 | — | — |
SD, standard deviation; ALT, alanine aminotransferase; HIV, human immunodeficiency virus; MSM, men who have sex with men; HAART, highly active antiretroviral therapy; CD, cluster of differentiation; RNA, ribonucleic acid; HCV, hepatitis C virus; IL28B, interleukin-28B; RVR, rapid virologic response; OR, odds ratio; CI, confidence interval.
*Values are numbers (percentages) unless otherwise indicated.
†Factors with a p value < 0.10 by univariate analysis entered multivariate analysis.
‡Patients with genotype 1 or 6 monoinfection and those with genotypes 1/2, or 1/6a mixed infection were categorized as predominant HCV genotype 1/6 infections.
¶The transient elastography (Fibroscan®, Echosens, Paris) failed to assess the stage of hepatic fibrosis in one chronic HCV-2/3 patient who achieved SVR after treatment.